The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected Patients
Figure 2
Changes in plasma concentration of MCP-1 after two years of followup in HIV-infected patients. A decrease in plasma MCP-1 concentration was observed in all HIV-infected patients, though it was more prominent and significant in those who did not display progression of atherosclerosis (a). Stratification according to antiretroviral treatment strategy (b) revealed that the decrease in plasma MCP-1 concentration was not significant in patients receiving TDF-FTC.
